MEDP Stock Chart & Stats
$8954.01
$1,931.98(27.51%)
At close: 4:00 PM EDT
$8954.01
$1,931.98(27.51%)
Day’s Range― - ―
52-Week Range$5,880.00 - $8,408.64
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$277.94B
Enterprise Value$14.76K
Total Cash (Recent Filing)$502.69M
Total Debt (Recent Filing)$120.10M
Price to Earnings (P/E)32.8
Beta0.13
Next Earnings
Oct 26, 2026EPS Estimate
76.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.39
Shares Outstanding27,911,655
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10,120.53Price Target Upside13.03% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)305.97
Revenue Forecast (FY)$49.49B
Bulls Say, Bears Say
Bulls Say
Exceptional Free Cash Flow GenerationMedpace's FCF roughly equals net income and is consistently strong on a TTM basis, providing durable internal funding for operations, share repurchases, and opportunistic investment. This high-quality cash generation cushions the business against trial timing variability and funds strategic priorities without needing heavy external financing.
Conservative Balance Sheet And Low LeverageLow debt and modest absolute borrowings give Medpace financial flexibility to sustain operations through cyclical trial delays, fund backlog conversion, and pursue buybacks or M&A. A conservative capital structure limits refinancing risk and preserves optionality over the medium term.
Robust Bookings And Sizable Backlog Providing VisibilityRecord net bookings and a multi-billion dollar backlog give durable revenue visibility and underpin management's multi-quarter growth guidance. A large convertable backlog supports headcount utilization and predictable revenue recognition over the next 12 months, moderating reliance on near-term new awards.
Bears Say
Slowing Revenue Growth Versus Prior YearsRevenue growth has materially decelerated on a TTM basis compared with prior rapid expansion, indicating Medpace may be entering a more mature phase. Slower topline expansion pressures operating leverage, reduces upside to margins over time, and raises reliance on backlog conversion and win rates to re-accelerate growth.
Customer Concentration RiskA heavy revenue share from a handful of large customers increases exposure to program funding shifts and renegotiations. Timing or cancellation of a single large program can swing revenue materially, complicating medium-term forecasting and elevating counterparty concentration risk.
Elevated Backlog Conversion And Visibility UncertaintyConversion rates above historical norms reflect gating and portfolio dynamics that may be temporary; management expects reversion but cannot time it. This elevated, variable conversion impairs revenue predictability and can create quarter-to-quarter volatility in reported revenue and resource planning.
Medpace Holdings News
MEDP FAQ
What was Medpace Holdings’s price range in the past 12 months?
Medpace Holdings lowest stock price was $5880.00 and its highest was $8408.64 in the past 12 months.
What is Medpace Holdings’s market cap?
Medpace Holdings’s market cap is $277.94B.
When is Medpace Holdings’s upcoming earnings report date?
Medpace Holdings’s upcoming earnings report date is Oct 26, 2026 which is in 87 days.
How were Medpace Holdings’s earnings last quarter?
Medpace Holdings released its earnings results on Jul 22, 2026. The company reported $74.203 earnings per share for the quarter, beating the consensus estimate of $69.454 by $4.749.
Is Medpace Holdings overvalued?
According to Wall Street analysts Medpace Holdings’s price is currently Undervalued.
Does Medpace Holdings pay dividends?
Medpace Holdings does not currently pay dividends.
What is Medpace Holdings’s EPS estimate?
Medpace Holdings’s EPS estimate is 76.95.
How many shares outstanding does Medpace Holdings have?
Medpace Holdings has 27,911,655 shares outstanding.
What happened to Medpace Holdings’s price movement after its last earnings report?
Medpace Holdings reported an EPS of $74.203 in its last earnings report, beating expectations of $69.454. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medpace Holdings?
Currently, no hedge funds are holding shares in MX:MEDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medpace Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10,120.53 (13.03% Upside)
$10,120.53 (13.03% Upside)
Blogger Sentiment
Bullish
MX:MEDP Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $282.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.89%
Trailing 12-Months
Company Description
Medpace Holdings
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
MEDP Company Deck
MEDP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid financial and operational momentum: double‑digit revenue and EBITDA growth, sizable net new awards and backlog growth, strong cash generation, share repurchases, and constructive guidance for 2026. Management noted improving RFP and funding dynamics and moderation of cancellations in Q2. Key risks discussed include prior cancellation volatility, an elevated backlog conversion rate versus historical norms (driven by gating policies and portfolio composition), higher reimbursable costs in H1, and customer concentration. Overall, the positive financial results, record net bookings, and upward guidance outweigh the operational risks and uncertainties discussed.View all MX:MEDP earnings summariesMEDP Revenue Breakdown
98.00% U.S.
2.00% Other
MEDP Stock 12 Month Forecast
Average Price Target
$10,120.53
▲(13.03% Upside)